“About
Vivaldi”
With operations at the Research Innovation Center at Colorado State University, Fort Collins, Colorado and in Vienna, Austria, Vivaldi Biosciences is developing Delta NS1 vaccines for protection against epidemic and pandemic viral respiratory diseases. NGN Capital LLC is the company’s lead investor.
Management & Board of Directors
Douglass B. Given, MD, PhD, MBA
CEO, Chairman
CEO, Vivaldi Biosciences Inc.
Chairman, Vivaldi Biosciences Inc.
Chairman, Supervisory Committee, Vivaldi Biosciences AG
Managing Partner, Health2047 Capital Partners
Venture capitalist and serial entrepreneur with extensive pharma and biotech executive and board experience, physician-scientist
• Bay City Capital
• Lilly
• Monsanto
• Schering Plough
• Mallinckrodt
Manfred Reiter, PhD
Sr. Vice President, Manufacturing - Managing Director, Vivaldi Biosciences AG
Biotech executive and expert in cell-based production, process development and scale-up for manufacturing vaccines and biologicals
• Nuvonis Technologies
• BlueSky Immunotherapies
• Hookipa Biotech
• Baxter International
Amy Aspelund
Vice President,
Research & Development
Vice President,
Research & Development
Expert leadership in gene cloning and sequencing, vaccine strain development and optimization, and assay development
• MedImmune
• University of California, San Francisco
• Colorado State University
• Onyx Pharmaceuticals
Carrie Brown, MSc
Vice President,
Marketing & Communications
Vice President,
Marketing & Communications
Heads corporate and investor communications, strategic planning, market intelligence, and media relations
• Progenitor, Inc.
• Genetic Engineering News
• Battelle Memorial Institute
• Gibco / Life Technologies
Evan Cuomo
Director of Finance
Heads finance, accounting and administration for Vivaldi Biosciences Inc. and Vivaldi Bioscience AG
• Stephen David Entertainment
• True Entertainment
• Eastern TV
Kenneth Abramowitz, MBA
Director
Director,Vivaldi Biosciences Inc.
Member, Supervisory Board, Vivaldi Biosciences AG
Managing General Partner, NGN Capital LLC
Health care venture investor with deep experience in fund management, mergers and buyouts; national security analyst and author
• The Carlyle Group
• Sanford C. Bernstein & Co.
Peter Johann, PhD
Director
Director, Vivaldi Biosciences Inc.
Member, Supervisory Board, Vivaldi Biosciences AG
Managing General Partner, NGN Capital LLC
Venture investor with extensive pharma industry experience including strategic planning, corporate development, M&A, marketing and licensing
• Boehringer Ingelheim
• Hoffmann-La Roche
• Boehringer Mannheim
Founders & Scientific Advisors
Peter Palese, PhD
Founder & Scientific Advisor, Vivaldi Biosciences Inc.
Professor & Chair Emeritus, Microbiology,
Professor, Medicine, Infectious Diseases,
Icahn School of Medicine at Mount Sinai
International leader in the study of viruses that cause respiratory diseases, influenza genomics, vaccines and antivirals, authored over 400 papers, holds multiple patents on vaccines and antivirals
• Member, National Academy of Sciences
• Member, Institute of Medicine
• Member, Austrian Academy of Sciences
• Member, German Academy of Sciences Leopoldina
• Member, American Academy of Arts and Sciences
Adolfo García-Sastre, PhD
Founder & Scientific Advisor, Vivaldi Biosciences Inc.
Director, Global Health and Emerging Pathogens Institute; Professor, Microbiology, Icahn School of Medicine at Mount Sinai
Expert in molecular biology of influenza and other negative strand RNA viruses, identified role of influenza NS1, co-developed reverse genetics techniques and live attenuated influenza viruses with modifications of NS1, authored over 480 papers and reviews
• Member, National Academy of Sciences
• Fellow, American Academy of Microbiology
• Fellow, Royal Academy of Pharmacy, Spain
Elliott Kieff, MD, PhD (1943-2024)
Founder & Scientific Advisor, Vivaldi Biosciences Inc.
Professor of Medicine, Emeritus, Harvard Medical School
Senior Physician, Brigham & Women’s Hospital
Expert in virology and medicine, led discoveries in genetics and molecular pathogenesis of Epstein-Barr virus infection resulting in development of vaccines and immunotherapeutics, authored more than 230 papers, holds 11 patents
• Member, National Academy of Sciences
• Member, Institute of Medicine
• Member, American Academy of Arts and Sciences